Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.
cabazitaxel
chemotherapy
clinical progression
metastatic castration-resistant prostate cancer
pain
taxanes
type of progression
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2021
13 Mar 2021
Historique:
received:
08
02
2021
revised:
03
03
2021
accepted:
07
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m Progression type at randomization was defined as follows: PSA progression only (PSA-p; no radiological progression (RADIO-p), no pain), RADIO-p (±PSA-p, no pain), or pain progression (PAIN-p, ±PSA-p, ±RADIO-p). Relationships between progression type and overall survival (OS), radiological progression-free survival (rPFS), and PSA response (confirmed PSA decrease ≥ 50%) were analyzed. All randomized patients ( This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.
Sections du résumé
BACKGROUND
BACKGROUND
In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m
METHODS
METHODS
Progression type at randomization was defined as follows: PSA progression only (PSA-p; no radiological progression (RADIO-p), no pain), RADIO-p (±PSA-p, no pain), or pain progression (PAIN-p, ±PSA-p, ±RADIO-p). Relationships between progression type and overall survival (OS), radiological progression-free survival (rPFS), and PSA response (confirmed PSA decrease ≥ 50%) were analyzed.
RESULTS
RESULTS
All randomized patients (
CONCLUSIONS
CONCLUSIONS
This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.
Identifiants
pubmed: 33805793
pii: cancers13061284
doi: 10.3390/cancers13061284
pmc: PMC8002173
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sanofi
ID : NA
Références
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2020 Sep 10;383(11):1040-1049
pubmed: 32905676
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur Urol. 2016 Aug;70(2):256-62
pubmed: 26610858
Eur Urol Oncol. 2018 Dec;1(6):467-475
pubmed: 31158090
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Lancet Oncol. 2013 Jul;14(8):760-8
pubmed: 23742877
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Pain. 1975 Sep;1(3):277-299
pubmed: 1235985
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
Future Oncol. 2011 Apr;7(4):497-506
pubmed: 21463139
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227
pubmed: 28117385
Eur J Cancer. 2020 Jan;125:142-152
pubmed: 31837907
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
Eur J Cancer. 2014 Jun;50(9):1617-27
pubmed: 24703899
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
N Engl J Med. 2020 Jun 4;382(23):2197-2206
pubmed: 32469184
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Ann Oncol. 2019 Dec 1;30(12):1992-2003
pubmed: 31560068
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660
pubmed: 32651468
Eur Urol. 2017 Feb;71(2):151-154
pubmed: 27477525
Eur Urol. 2014 Feb;65(2):505-7
pubmed: 24211139
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Eur J Cancer. 2020 Jan;125:153-163
pubmed: 31787484
J Clin Oncol. 2017 Oct 1;35(28):3189-3197
pubmed: 28753384
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890